Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
Evaluate Omnium
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Ranbaxy Laboratories
October 15, 2014
Shabbvie marks difference between great and exceptional deal quarter
June 27, 2014
Delayed Diovan generic emerges – Valcyte and Nexium next?
May 16, 2014
Novartis settles Gleevec as other patent fights continue
April 07, 2014
Daiichi’s ill-timed Indian foray ends in minority Sunbaxy stake
January 07, 2014
Biotech bull run leaves few big cap drug stocks down in 2013
October 22, 2013
Clock ticks for Ranbaxy as Novartis continues to reap Diovan revenues
October 01, 2013
Surging US drives strong drug stock performances at nine month stage
September 02, 2013
ESC – Daiichi joins the US-EU blood-thinning race with positive Lixiana data
July 03, 2013
Biotech continues to reward investors in first half
April 04, 2013
Biotech consolidates its dominance in the first quarter
September 28, 2012
Supreme Court could be next up in "pay for delay" saga
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
October 20, 2020
Finding the next Vertex
October 15, 2020
Clinical setback lays bare Vertex’s weakness
October 15, 2020
SITC 2020 – embargo snafu triggers the first movers
October 19, 2020
Biopharma buyouts still pricey
September 30, 2020
More biotechs test the third way to market
